Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Mol Cancer Ther. 2020 Dec 2;20(2):263–273. doi: 10.1158/1535-7163.MCT-20-0365

Figure 2. Radiosensitization by olaparib and AZD6738 in HR proficient and HR deficient pancreatic cancer cells.

Figure 2.

Representative radiation survival curves for MiaPaCa2 shRAD51-expressing cells in the absence (A) or presence (B) of dox, Panc1 (C) or Capan1 (D) cells treated with 100 nM AZD6738 and/or olaparib beginning one hour pre- and continuing 24 hours post-radiation (RT). For mean radiation enhancement ratios (RER), survival data and statistical analyses, see Table 1A.